IASLC TTLC 2026 spotlights patient voices, ctDNA MRD, EGFR co-mutations, and ADCs—plus real-world gaps in testing and multidisciplinary lung care.
Sabrina Serani
Sabrina Serani is the managing editor for Targeted Oncology, covering breast, lung, and brain cancers. Contact her at sserani@targetedonc.com.
Articles by Sabrina Serani
ASCO updates stage IV driver-negative NSCLC guidance: put molecular testing first, add Teliso‑V, and navigate murky frontline choices.
Trilaciclib protects bone marrow before SCLC chemotherapy, sharply reducing neutropenia, anemia, and thrombocytopenia, improving fatigue and keeping treatment on schedule without weakening tumor kill.
An interview with Joshua Reuss, MD, thoracic medical oncologist at Georgetown University and co-author of the guidelines.
Results from the 992-patient study will be presented at an upcoming medical meeting; FDA review of giredestrant is ongoing based on data from the positive evERA trial.
Compare T-DXd, sacituzumab, and dato-DXd in HR+ metastatic breast cancer—key trial results, side effects, and sequencing insights.
FDA grants priority review to T-DXd for high-risk HER2-positive early breast cancer with residual disease, after trial shows markedly better recurrence-free survival than T-DM1.
New data push the use of ADCs earlier, reshaping HER2+ metastatic breast cancer sequencing, maintenance, and trial strategies.
FDA clears real-time AI OCT to spot breast cancer margins during lumpectomy, helping surgeons reduce repeat operations and improve outcomes.
New study links Medicaid expansion to sustained breast cancer survival gains, revealing uneven benefits by race and urging policy action.
FDA clears zongertinib for HER2-mutant advanced nonsquamous NSCLC, showing strong responses and promising brain metastasis activity.
Phase 3 interim data show izalontamab brengitecan boosts survival in pretreated metastatic triple‑negative breast cancer, hinting at new standard.
FDA fast tracks ART6043, an oral Polθ inhibitor for gBRCA HER2-negative metastatic breast cancer, showing early activity and potential to overcome PARP resistance.
FDA reviews oral giredestrant plus everolimus for ESR1-mutated ER+ metastatic breast cancer after CDK4/6 failure, with strong PFS gains and manageable safety.
How ancestry, neighborhood stress and chemo side effects shape TNBC outcomes—and why immunotherapy and tailored care can narrow survival gaps.
Discover how AI accelerates precision cancer care, streamlines trials, and tackles bias and liability—what oncologists need to know now.
Discover how precision lung cancer care tackles gene fusions, new HER2/ROS1/ALK drugs, expanded screening, and liquid biopsies shaping 2026 treatment.
Cancer survival hits 70% as early screening and immunotherapy advance—yet survivorship needs and Indigenous disparities demand urgent action.
FDA approves monthly subcutaneous amivantamab plus lazertinib for EGFR-mutated advanced NSCLC, cutting clinic time and infusion reactions while maintaining efficacy.
Adjuvant selpercatinib boosts event-free survival after surgery in early-stage RET fusion–positive NSCLC, signaling a potential new standard and expanding genomic testing.
Dr Manmeet Ahluwalia explores how precision oncology and targeted therapies are transforming brain metastases care, extending survival from months to years.
Global phase 3 trial tests safusidenib maintenance after chemoradiotherapy, aiming to delay recurrence and improve survival in IDH1-mutant astrocytoma.
FDA RMAT boosts inhaled gene therapy KB707, delivering IL‑2/IL‑12 to lung tumors; early trial shows responses with manageable safety.
Brittany Dulmage, MD, discusses why a popular ingredient in hair, skin, and nails vitamins may not be a safe option for patients undergoing cancer treatment.
FDA strengthens capecitabine and 5‑FU labels: DPD deficiency can trigger fatal toxicity; consider testing, lower doses, and prompt antidote.
Phase 2 trial tests azacitidine plus venetoclax in therapy-related high-risk MDS, showing remissions and better posttransplant survival despite TP53 mutations.
TNBC care shifts to TROP2 ADCs plus immunotherapy, highlighting early relapse needs, sequencing dilem
FDA prioritizes review of datopotamab deruxtecan for treating metastatic triple-negative breast cancer, showing significant survival benefits over chemotherapy.
New data reveals CD47 expression as a key biomarker for predicting evorpacept's effectiveness in treating HER2-positive metastatic breast cancer.